Test ID CATN Calcitonin, Serum
Useful For
Diagnosis and follow-up of medullary thyroid carcinoma
Adjunct to diagnosis of multiple endocrine neoplasia type II and familial medullary thyroid carcinoma
Occasionally useful in the diagnosis and follow-up of islet cell tumors
Method Name
Automated Immunochemiluminometric Assay (ICMA)
Reporting Name
Calcitonin, SSpecimen Type
SerumCollection Container/Tube:
Preferred: Serum gel
Acceptable: Red top
Submission Container/Tube: Plastic vial
Specimen Volume: 0.8 mL
Collection Instructions:
1. After draw immediately place specimen on ice.
2. Refrigerate specimen during centrifugation and immediately transfer serum to a plastic vial.
Forms: If not ordering electronically, complete, print, and send an Oncology Test Request Form (T729) with the specimen
(http://www.mayomedicallaboratories.com/it-mmfiles/oncology-request-form.pdf)
Specimen Minimum Volume
0.4 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Serum | Frozen | 15 days |
Clinical Information
In the normal physiological situation, calcitonin is a polypeptide hormone secreted by the parafollicular cells (also referred to as calcitonin cells or C cells) of the thyroid gland. The main action of calcitonin is the inhibition of bone resorption by regulating the number and activity of osteoclasts. Calcitonin is secreted in direct response to serum hypercalcemia and may prevent large oscillations in serum calcium levels and excessive loss of body calcium. However, in comparison to parathyroid hormone and 1,25-dihydroxyvitamin D, the role of calcitonin in the regulation of serum calcium in humans is minor. Measurements of serum calcitonin levels are, therefore, not useful in the diagnosis of disorders of calcium homeostasis.
Malignant tumors arising from thyroid C cells (medullary thyroid carcinoma: MTC) usually produce elevated levels of calcitonin. MTC is an uncommon malignant thyroid tumor, comprising <5% of all thyroid malignancies. Approximately 25% of these cases are familial, usually appearing as a component of multiple endocrine neoplasia type II (MENII, Sipple syndrome). MTC may also occur in families without other associated endocrine dysfunction, with similar autosomal dominant transmission as MENII, which is then called familial medullary thyroid carcinoma (FMTC). Mutations in the RET proto-oncogene are associated with MENII and FMTC.
Other neuroectodermal endocrine tumors, particularly islet cell tumors, may also produce calcitonin, but do so much less frequently. Calcitonin elevations also may occur with:
-Cancer of the lung, breast, or pancreas
-Intestinal, gastric, or bronchial carcinoids
-Chronic renal failure, Zollinger-Ellison syndrome, or pernicious anemia
-Pregnant females at term
-Newborns
Reference Values
BASAL
Males: <16 pg/mL
Females: <8 pg/mL
PEAK CALCIUM INFUSION
Males: ≤130 pg/mL
Females: ≤90 pg/mL
Cautions
This test is not useful for evaluating calcium metabolic diseases.
Falsely elevated values may occur in serum from patients who have developed human antimouse antibodies or heterophilic antibodies.
Values obtained with different assay methods or kits may be different and cannot be used interchangeably. Test results cannot be interpreted as absolute evidence for the presence or absence of malignant disease.
Day(s) Performed
Monday through Friday; 5 a.m.-12 a.m.
Saturday; 6 a.m.-6 p.m.
Report Available
Same day/1 dayPerforming Laboratory

Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82308